Nivolumab: Targeting PD-1 to bolster antitumor immunity

Julie R. Brahmer, Hans Hammers, Evan J. Lipson

Research output: Contribution to journalArticle

97 Scopus citations

Abstract

Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and can restore anticancer immune responses by abrogating PD-1 pathway-mediated T-cell inhibition. Nivolumab is approved in Japan and the USA for the treatment of patients with advanced melanoma. A Phase I trial reported overall objective response rates of 17, 32 and 29 in patients with advanced non-small-cell lung cancer, melanoma and renal cell carcinoma, respectively, which included many heavily pretreated patients. 1-/2-year overall survival rates were 42/24, 63/48 and 70/50 for non-small-cell lung cancer, melanoma and renal cell carcinoma, respectively. Nivolumab significantly improved survival versus dacarbazine in previously untreated patients with metastatic melanoma in a Phase III trial. Nivolumab is associated with a manageable adverse event profile. Numerous clinical trials are investigating nivolumab alone or in combination with other therapies in multiple cancer settings. This article summarizes the development of nivolumab as of November 2014.

Original languageEnglish (US)
Pages (from-to)1307-1326
Number of pages20
JournalFuture Oncology
Volume11
Issue number9
DOIs
StatePublished - Jan 1 2015

    Fingerprint

Keywords

  • immune checkpoint inhibitors
  • immunotherapy
  • lung cancer
  • melanoma
  • nivolumab
  • PD-1
  • programmed death-1
  • renal cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this